Tags

Type your tag names separated by a space and hit enter

Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
Med Oncol 2015; 32(1):307MO

Abstract

Pirarubicin (THP), a novel anthracycline derivative of doxorubicin (ADM), is effective in treating patients with advanced, relapsed or recurrent high-grade osteosarcoma. But its role in neoadjuvant/adjuvant chemotherapy of osteosarcoma is still not defined. We conducted a retrospective evaluation of THP-containing chemotherapy for osteosarcoma in comparison with ADM-containing chemotherapy to determine differences in efficacy and toxicities between THP- and ADM-containing regimens. From January 2008 to May 2011, 112 stage IIB limb high-grade osteosarcoma patients were treated in our institute. Fifty-four patients received a median 6 cycles of neoadjuvant/adjuvant chemotherapy consisted of THP (pirarubicin), DDP (cisplatin), IFO (ifosfamide) and MTX (methotrexate), while 58 patients received a median 6 cycles of neoadjuvant/adjuvant chemotherapy consisted of ADM (doxorubicin), DDP (cisplatin), IFO (ifosfamide) and MTX (methotrexate). Efficacy and toxicity of the 2 anthracyclines given as combination chemotherapy were assessed in these patients. The limb salvage rate, histologic response rate, 2-year recurrence rate, 2-year metastasis rate, 2-year disease-free survival rate, 2-year overall survival rate, median disease-free survival time (DFS) and median overall survival time (OS) in THP-containing group were similar to that in ADM-containing group. Toxicities were well balanced in two groups. No death related to chemotherapy was observed. Left ventricular ejection fraction was unchanged 1 and 2 years after chemotherapy in two groups. Efficacy and toxicity of THP-containing combination are similar to those of ADM-containing combination in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma.

Authors+Show Affiliations

Department of Oncology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, No. 600, Yishan Road, Xuhui District, Shanghai, 200233, People's Republic of China, old.007@hotmail.com.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25432694

Citation

Yu, Wenxi, et al. "Pirarubicin Versus Doxorubicin in Neoadjuvant/adjuvant Chemotherapy for Stage IIB Limb High-grade Osteosarcoma: Does the Analog Matter?" Medical Oncology (Northwood, London, England), vol. 32, no. 1, 2015, p. 307.
Yu W, Tang L, Lin F, et al. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter? Med Oncol. 2015;32(1):307.
Yu, W., Tang, L., Lin, F., Yao, Y., & Shen, Z. (2015). Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter? Medical Oncology (Northwood, London, England), 32(1), p. 307. doi:10.1007/s12032-014-0307-y.
Yu W, et al. Pirarubicin Versus Doxorubicin in Neoadjuvant/adjuvant Chemotherapy for Stage IIB Limb High-grade Osteosarcoma: Does the Analog Matter. Med Oncol. 2015;32(1):307. PubMed PMID: 25432694.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter? AU - Yu,Wenxi, AU - Tang,Lina, AU - Lin,Feng, AU - Yao,Yang, AU - Shen,Zan, Y1 - 2014/11/29/ PY - 2014/06/04/received PY - 2014/07/01/accepted PY - 2014/11/30/entrez PY - 2014/11/30/pubmed PY - 2016/1/27/medline SP - 307 EP - 307 JF - Medical oncology (Northwood, London, England) JO - Med. Oncol. VL - 32 IS - 1 N2 - Pirarubicin (THP), a novel anthracycline derivative of doxorubicin (ADM), is effective in treating patients with advanced, relapsed or recurrent high-grade osteosarcoma. But its role in neoadjuvant/adjuvant chemotherapy of osteosarcoma is still not defined. We conducted a retrospective evaluation of THP-containing chemotherapy for osteosarcoma in comparison with ADM-containing chemotherapy to determine differences in efficacy and toxicities between THP- and ADM-containing regimens. From January 2008 to May 2011, 112 stage IIB limb high-grade osteosarcoma patients were treated in our institute. Fifty-four patients received a median 6 cycles of neoadjuvant/adjuvant chemotherapy consisted of THP (pirarubicin), DDP (cisplatin), IFO (ifosfamide) and MTX (methotrexate), while 58 patients received a median 6 cycles of neoadjuvant/adjuvant chemotherapy consisted of ADM (doxorubicin), DDP (cisplatin), IFO (ifosfamide) and MTX (methotrexate). Efficacy and toxicity of the 2 anthracyclines given as combination chemotherapy were assessed in these patients. The limb salvage rate, histologic response rate, 2-year recurrence rate, 2-year metastasis rate, 2-year disease-free survival rate, 2-year overall survival rate, median disease-free survival time (DFS) and median overall survival time (OS) in THP-containing group were similar to that in ADM-containing group. Toxicities were well balanced in two groups. No death related to chemotherapy was observed. Left ventricular ejection fraction was unchanged 1 and 2 years after chemotherapy in two groups. Efficacy and toxicity of THP-containing combination are similar to those of ADM-containing combination in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma. SN - 1559-131X UR - https://www.unboundmedicine.com/medline/citation/25432694/Pirarubicin_versus_doxorubicin_in_neoadjuvant/adjuvant_chemotherapy_for_stage_IIB_limb_high_grade_osteosarcoma:_does_the_analog_matter L2 - https://dx.doi.org/10.1007/s12032-014-0307-y DB - PRIME DP - Unbound Medicine ER -